Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines
复制标题
DOI：
10.1086/315298
复制
发表时间：
2000-03-01
影响因子：
6.4
通讯作者：
Jimenez, E
中科院分区：
文献类型：
--
作者：
Borkowsky, W;Wara, D;Jimenez, E
母亲感染人类免疫缺陷病毒1型（HIV-1）的儿童在出生时以及1、3和5个月时接种3剂由SF-2或MN HIV-1毒株制备的重组gp 120疫苗中的1剂。共有126名儿童未被感染; 21名仅接受佐剂。疫苗接种者发生淋巴组织增生反应的次数大于或等于2次，对同源HIV-1抗原的反应比佐剂接种者更频繁（56%对14%; P <0.001）。在2次免疫接种后，应答得到赞赏，并在最后一次免疫接种后维持>84周。在加速免疫接种方案（出生、2周、2个月和5个月）中，SF-2疫苗的最低剂量在所有11名接种者中产生应答，持续4周。还检测到对异源包膜抗原的应答。在可以预防某些感染（围产期或母乳暴露相关）的年龄，接种疫苗可获得免疫应答。
Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of recombinant gp 120 vaccines prepared from SF-2 or MN strains of HIV-1. A total of 126 children were not infected; 21 received adjuvant only. Vaccine recipients developed lymphoproliferative responses on greater than or equal to 2 occasions, responding more often to homologous HIV-1 antigens than did adjuvant recipients (56% vs. 14%; P < .001). Responses were appreciated after 2 immunizations and were maintained for >84 weeks after the last immunization, hn accelerated immunization schedule(birth, 2 weeks, 2 months, and 5 months) with the lowest dose of the SF-2 vaccine produced responses in all 11 vaccinees by 4 weeks. Responses to heterologous envelope antigens were also detected. Immune responses to vaccination are achievable at an age when some infection (perinatal or breast milk exposure related) may be prevented.